Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved

M. Nemčeková, S. Čarnická, M. Ferko, M. Muráriková, V. Ledvényiová, T. Ravingerová

. 2013 ; 62 (5) : 577-584.

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

Hypolipidemic compound pirinixic acid (WY-14643, WY) is known to exert pleiotropic (other than primary) effects, such as activation of peroxisome proliferator-activated receptors (PPAR-alpha), transcription factors regulating different cardiac functions. Their role in ischemia-reperfusion (I/R) injury and cardioprotection is less clear, although protective effects of PPAR agonists have been documented. This study was designed to explore the effects of WY on the I/R injury in the rat heart and potential mechanisms involved, including mitochondrial K(ATP) channels (mitoK(ATP)) opening and production of reactive oxygen species (ROS). Langendorff-perfused hearts of rats intragastrally treated with WY (3 mg/kg/day) for 5 days and of control animals were subjected to 30-min global ischemia and 2-h reperfusion with or without 15-min perfusion with mitoK(ATP) blocker 5-hydroxydecanoate (5-HD) prior to I/R. Evaluation of the infarct size (IS, TTC staining) served as the main end-point of protection. Lipid peroxidation (a marker of ROS production) was determined by measurement of myocardial concentration of conjugated dienes (CD), whereas protein expression of endothelial NO synthase was analysed by Western blotting. A 2-fold increase in the cardiac protein levels of eNOS after treatment with WY was accompanied by lower post-I/R levels of CD compared with those in the hearts of untreated controls, although WY itself enhanced ROS generation prior to ischemia. IS was reduced by 47 % in the hearts of WY-treated rats (P<0.05), and this effect was reversed by 5-HD. Results suggest that PPAR-alpha activation may confer protection against lethal I/R injury in the rat heart that involves up-regulation of eNOS, mitoK(ATP) opening and reduced oxidative stress during I/R.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14066027
003      
CZ-PrNML
005      
20140731110227.0
007      
ta
008      
140722s2013 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.932591 $2 doi
035    __
$a (PubMed)24020817
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Nemčeková, Mária, $d 1947- $7 xx0079036 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
245    10
$a Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved / $c M. Nemčeková, S. Čarnická, M. Ferko, M. Muráriková, V. Ledvényiová, T. Ravingerová
520    9_
$a Hypolipidemic compound pirinixic acid (WY-14643, WY) is known to exert pleiotropic (other than primary) effects, such as activation of peroxisome proliferator-activated receptors (PPAR-alpha), transcription factors regulating different cardiac functions. Their role in ischemia-reperfusion (I/R) injury and cardioprotection is less clear, although protective effects of PPAR agonists have been documented. This study was designed to explore the effects of WY on the I/R injury in the rat heart and potential mechanisms involved, including mitochondrial K(ATP) channels (mitoK(ATP)) opening and production of reactive oxygen species (ROS). Langendorff-perfused hearts of rats intragastrally treated with WY (3 mg/kg/day) for 5 days and of control animals were subjected to 30-min global ischemia and 2-h reperfusion with or without 15-min perfusion with mitoK(ATP) blocker 5-hydroxydecanoate (5-HD) prior to I/R. Evaluation of the infarct size (IS, TTC staining) served as the main end-point of protection. Lipid peroxidation (a marker of ROS production) was determined by measurement of myocardial concentration of conjugated dienes (CD), whereas protein expression of endothelial NO synthase was analysed by Western blotting. A 2-fold increase in the cardiac protein levels of eNOS after treatment with WY was accompanied by lower post-I/R levels of CD compared with those in the hearts of untreated controls, although WY itself enhanced ROS generation prior to ischemia. IS was reduced by 47 % in the hearts of WY-treated rats (P<0.05), and this effect was reversed by 5-HD. Results suggest that PPAR-alpha activation may confer protection against lethal I/R injury in the rat heart that involves up-regulation of eNOS, mitoK(ATP) opening and reduced oxidative stress during I/R.
650    _2
$a zvířata $7 D000818
650    _2
$a kardiotonika $x farmakologie $7 D002316
650    _2
$a cytoprotekce $7 D019610
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a hypolipidemika $x farmakologie $7 D000960
650    _2
$a peroxidace lipidů $x účinky léků $7 D015227
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a kontrakce myokardu $x účinky léků $7 D009200
650    _2
$a infarkt myokardu $x metabolismus $x patologie $x patofyziologie $x prevence a kontrola $7 D009203
650    _2
$a reperfuzní poškození myokardu $x metabolismus $x patologie $x patofyziologie $x prevence a kontrola $7 D015428
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a synthasa oxidu dusnatého, typ III $x metabolismus $7 D052250
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a PPAR alfa $x agonisté $x metabolismus $7 D047493
650    _2
$a perfuze $7 D010477
650    _2
$a blokátory draslíkových kanálů $x farmakologie $7 D026902
650    _2
$a draslíkové kanály $x účinky léků $x metabolismus $7 D015221
650    _2
$a pyrimidiny $x farmakologie $7 D011743
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a časové faktory $7 D013997
650    _2
$a funkce levé komory srdeční $7 D016277
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Čarnická, Slávka $7 xx0146449 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Ferko, Miroslav $7 xx0074241 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Muráriková, M. $7 _AN079212 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Ledvényiová, V. $7 _AN070794 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Ravingerová, Táňa, $d 1951- $7 xx0248557 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 62, č. 5 (2013), s. 577-584
856    41
$u http://www.biomed.cas.cz/physiolres/archive.htm $y domovská stránka časopisu - plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20140722 $b ABA008
991    __
$a 20140730092217 $b ABA008
999    __
$a ok $b bmc $g 1034311 $s 864803
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 62 $c 5 $d 577-584 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20140722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...